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The paediatric respiratory research community uses cohort studies extensively. However, the 
landscape of these studies and their quality of reporting has not been assessed. 
We performed a systematic review of publications on cohort studies reporting on paediatric 
lower respiratory problems published in 2018. We searched Medline and EMBASE and 
extracted data on the studies’ and journals’ characteristics. We assessed the number of items 
of the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) 
checklist that a random sample (100 papers) reported. We analysed factors associated with 
the STROBE score and with the most poorly reported items, using Poisson and logistic 
regression 
Of the 21 319 records identified, 369 full-text articles met our inclusion criteria. Most papers 
studied asthma aetiology through birth cohorts and were based in Europe or North America. 
The reporting quality was insufficient: 15% reported the 22 STROBE items; median score: 18 
(IQR: 16-21). The most poorly reported items were: sources of bias, sample size, statistical 
methods, descriptive results and generalisability. None of the studies’ or journals’ factors were 
associated with the STROBE score.  
We need a joined effort of editors, reviewers and authors to improve the reporting quality of 










Cohort studies are extensively used in paediatric respiratory research to investigate risk 
factors, incidence and natural history of disease. The strengths of the longitudinal design 
include establishing temporality and reducing information bias. However, the study design has 
limitations, like high costs, selection bias, attrition bias, and residual confounding. There are 
solutions to overcome or mitigate these disadvantages like retrospective cohort design, nested 
case-control studies or linkage to nationwide available datasets. The use of these strategies, 
the type of questions investigated and the quality of reporting of cohort studies has not been 
assessed in paediatric respiratory research. 
Adequate reporting is key for reproducibility of research and translation of results into clinical 
practice. STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) is an 
international, multidisciplinary and collaborative initiative started in 2004 to enhance the 
reporting quality and dissemination of observational studies [1]. The STROBE statement is 
being increasingly endorsed by journals, but mandatory submission of its checklist is not yet 
common practice for observational studies as it is for randomized controlled trials. Studies 
assessing the fulfilment of the STROBE criteria suggest that reporting quality is generally poor 
and that some items are frequently underreported [2-4]. Certain factors have been associated 
with reporting quality, such as journal’s impact factor and STROBE endorsement policy, the 
authors’ affiliation, and publication type (peer reviewed or not) [3,5-7]. Identifying which 
STROBE items are commonly misreported in paediatric respiratory cohort papers and which 
modifiable factors are associated with poor reporting may raise awareness and help improve 
the quality of publications in this area. We therefore conducted a systematic review of papers 
published in 2018 to present the landscape of cohort studies addressing paediatric lower 
respiratory problems, to describe the reporting quality of these papers according to STROBE 




The predefined review protocol that we followed for this systematic review has been 
registered in the Open Science Framework (OSF) repository (Registration DOI 
10.17605/OSF.IO/F8X3B). We used the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA, research checklist online) [8] to report our findings. 
 
Eligibility criteria 
We searched for papers reporting on lower respiratory problems from paediatric cohort 
studies worldwide, published in 2018 in peer-reviewed journals. For this we used all the 
following specific inclusion criteria: (1) cohort study design (exposure measured before 
outcome, with at least two time points with prospective data collection), including nested 
case-control studies; (2) children under 18 years of age at study baseline, or with separate 
results reported for children, or for rare diseases, if more than 50% of the study population 
were children; (3) lower respiratory problems and evaluations of lower respiratory health as 
outcomes (including respiratory symptoms, test results such as lung function, diagnosis and 
prognosis) or lower respiratory problems and evaluations of lower respiratory health as 
exposures (including respiratory symptoms, test results such as lung function, diagnosis, 
management and prognosis). 
We excluded studies with any of the following criteria: (1) reports not in English, (2) published 
before 1st January 2018 or after 31st December 2018, (3) non-original papers (conference 
abstracts, editorials and reviews), (4) follow-up time <3 months (to exclude papers on short-
term outcomes of hospitalised patients), and (5) studies with <50 participants to exclude small 
case series (for rare diseases where smaller sample sizes are expected we excluded if there 
were <20 participants). If exact sample size was not stated but we could assure that it was 




Information sources and search strategy 
We searched Medline and EMBASE from 1st January 2018 to 31st December 2018, on April 17th 
2019. We used a reference management software (EndNote X8, Thomson Reuters) to import 




One reviewer screened titles and abstracts to assess eligibility according to the described 
criteria. In a second step, a single reviewer screened full-text papers of selected studies and 
recorded the reasons for exclusion in an Excel form. 
 
Data extraction 
We extracted data from the selected papers using a standardised pre-piloted data collection 
Excel form. We extracted information on the characteristics of the manuscript (author, journal, 
location and year of publication) and the study (cohort name and size, study design, type of 
research question, main diseases of interest, source of exposure and outcome data, use of 
longitudinal analysis, follow-up time and age at baseline). We did not include a risk of bias 
assessment, as the results were not extracted and evaluated. 
 
Definitions 
Journals were classified into thematic categories according to the InCites Journal Citation 
Report classification. If a journal appeared in two different categories, it was classified as the 
first in which it appeared in this order: respiratory, allergy, infectious diseases, public health/ 
epidemiology/ environment, paediatrics, general medicine and any other category 
(Supplementary Table 1). The diagnoses studied were grouped into: asthma or wheeze, 
respiratory infectious diseases, rare diseases (defined as occurring in fewer than 1 in 2000 
 
 
people, and including bronchopulmonary dysplasia, diaphragmatic hernia, cystic fibrosis and 
primary ciliary dyskinesia), lung function in healthy children and other problems (including 
cough, respiratory distress syndrome, pneumothorax and unspecific respiratory symptoms). 
 
Assessment of reporting quality 
We selected a random sample of 100 (27%) of the included papers and assessed how close the 
manuscript followed the STROBE recommendations for the reporting of cohort studies. We 
used a standardised data collection Excel form and recorded the adherence to each of the 22 
items present in the STROBE checklist for the reporting of cohort studies. The STROBE 
statement recommends the reporting of all the elements in their checklist. For this reason, we 
considered insufficient reporting if not all the elements (22) were reported. We did not 
evaluate the items that are only ‘suggested’, such as the inclusion of a flow diagram. We 
defined an item as not reported if it was not present or insufficiently reported.  For example, for 
item 7, if they defined the outcome and main exposure, but not other variables (e.g. 
confounders and important effect modifiers). To examine characteristics associated with 
reporting quality, we also extracted information of variables that have been previously 
associated with reporting: journal’s impact factor, percentage ranking, category, reporting 
recommendations and if it belonged to a scientific society; and the study’s location, research 
question and main diagnosis of interest. We used data from the InCites Journal Citation Report  
to record the impact factor and ranking of the journal where the manuscript was published, and 
from the  journals’ webpages to collect information on whether the journal belonged to a 
scientific society and on the reporting recommendations (classified into no recommendation 
(none), recommending to follow any reporting guideline, recommending to follow STROBE 





Synthesis of results and analysis 
We summarised the results (absolute numbers and proportions) of the study characteristics, 
the journals where they were published and the reporting quality according to the STROBE 
statement using tables and graphs. We used Poisson regression to study univariable 
associations between the study’s characteristics and the number of items from the STROBE 
checklist that were reported in the manuscript. We reported the rate ratio with 95% confidence 
interval, and the p value of the likelihood ratio test. We then applied logistic regression to study 
univariable associations between the study’s characteristics and the reporting of the 4 items 
from the STROBE checklist that were most poorly reported: item 9 (bias), item 12 (statistics), 
item 14 (descriptive results) and item 21 (generalisability). We reported the odds ratio with 95% 
confidence interval for each item separately. For both regression analyses, we included the 
following factors based on previous findings and plausibility of association with reporting 
quality: journal’s impact factor, ranking, category, reporting recommendations and if it 
belonged to a scientific society; and the study’s location, research question and main diagnosis 




Of the 15 846 records identified through database searching, 890 were selected based on title 
and abstract and 369 full-text articles were finally included in the systematic review (Figure 1). 
Of the 521 full-text articles excluded, 77 were not a cohort study and 24 did not include a 
longitudinal analysis (e.g. used cross-sectional data from a cohort study). 
Most studies were located in Europe (161, 44%) or North America (108, 29%), with few from 
other locations, especially Africa (17, 5%) and South America (12, 3%) (Figure 2). The median 
sample size was of 746 children (IQR 187-4535). Forty one percent of the studies had a birth or 
pregnancy cohort design, followed by prospective clinical cohorts (109, 30%) and non-birth 
 
 
population-based cohorts (56, 15%). Median follow-up time was 5 years (IQR: 1-10 years). A 
quarter (85, 23%) used linkage with routine datasets and there were very few nested case-
control studies (7, 2%). The most frequent sources of exposure data were questionnaires/ 
interviews (128, 35%) or direct examination/ diagnostic tests (134, 36%), while outcomes were 
normally obtained from questionnaires/ interviews (157, 43%). 
The main diagnosis of interest in the included studies was asthma or wheeze (214, 58%) and the 
main research questions related to aetiology (194, 53%) followed by natural history or 
prognosis (116, 31%). The research questions varied by diagnosis of interest (Figure 3a). Studies 
on asthma and lung function answered questions mostly on aetiology or risk factors, while 
natural history and prognosis was more common in studies of rare diseases and other 
diagnoses. Disease phenotyping was mostly studied in papers on respiratory infectious diseases 
or rare diseases. Similarly, sample size of the study population also varied by diagnosis of 
interest (Figure 3b). More than half of the studies on asthma had more than 1000 participants, 
while 40% of those on rare diseases had less than 100 participants.  
The included cohort studies were mostly published in respiratory (103, 28%) or 
allergy/immunology journals (88, 24%) (Figure 2). Of the individual journals, those with 10 or 
more papers were either highly specific (Paediatric pulmonology, Paediatric Allergy& 
Immunology and Journal of Asthma) or high impact respiratory journals (Journal of Allergy and 
Clinical Immunology, Thorax and European Respiratory Journal). There was only one general 
journal (PlosONE) with 10 or more included papers (data not shown). There were some 
differences in the study design, sample size and research question between journals, though 
the largest differences were observed in the diagnosis of interest (Supplementary Table 2). 
Papers on asthma were published mainly in allergy/immunology or respiratory journals and 
those on respiratory infectious diseases in their respective journals. Papers on other diagnoses 
were more evenly distributed, with the exception of the allergy/immunology journals that 
published almost exclusively on asthma. 
 
 
Table 1: Number of manuscripts that accurately followed each of the STROBE checklist items 




Recommendation N  
 Title and 
abstract 
1 All criteria for item 1 81 
(a) Indicate the study’s design with a commonly used term in the title or the 
abstract 
83 
(b) Provide in the abstract an informative and balanced summary of what was 





2 Explain the scientific background and rationale for the investigation being 
reported 
100 
Objectives 3 State specific objectives, including any prespecified hypotheses 97 
Methods  
Study design 4 Present key elements of study design early in the paper 93 
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection 
90 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of 
participants. Describe methods of follow-up 
94 
(b) For matched studies, give matching criteria and number of exposed and 
unexposed 
- 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and 




8*  For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods if 
there is more than one group 
96 
Bias 9 Describe any efforts to address potential sources of bias 58 
Study size 10 Explain how the study size was arrived at 64 
Quantitative 
variables 
11 Explain how quantitative variables were handled in the analyses. If applicable, 




12 All criteria for item 12 38 
(a) Describe all statistical methods, including those used to control for 
confounding 
92 
(b) Describe any methods used to examine subgroups and interactions 83 
(c) Explain how missing data were addressed 43 
(d) If applicable, explain how loss to follow-up was addressed 59 
(e) Describe any sensitivity analyses 66 
Results  
Participants 13* All criteria for item 13 (except c) 72 
(a) Report numbers of individuals at each stage of study—eg numbers 
potentially eligible, examined for eligibility, confirmed eligible, included in the 
study, completing follow-up, and analysed 
78 
(b) Give reasons for non-participation at each stage 76 
(c) Consider use of a flow diagram - 
Descriptive data 14* All criteria for item 14 56 
(a) Give characteristics of study participants (eg demographic, clinical, social) 
and information on exposures and potential confounders 
90 
(b) Indicate number of participants with missing data for each variable of 
interest 
59 
(c) Summarise follow-up time (eg, average and total amount) 82 
Outcome data 15* Report numbers of outcome events or summary measures over time 98 
Main results 16 All criteria item 16 (except c) 82 
(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates 
and their precision (eg, 95% confidence interval). Make clear which confounders 
were adjusted for and why they were included 
84 
(b) Report category boundaries when continuous variables were categorized 98 
 
 
(c) If relevant, consider translating estimates of relative risk into absolute risk 
for a meaningful time period 
- 




Key results 18 Summarise key results with reference to study objectives 100 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias 
94 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and other 
relevant evidence 
96 
Generalisability 21 Discuss the generalisability (external validity) of the study results 51 
Other information  
Funding 22 Give the source of funding and the role of the funders for the present study and, 
if applicable, for the original study on which the present article is based 
84 
Colour code for proportion of manuscripts that reported each item:  
     <50%;       50-70%;        70-90%;         >90%    
Items in white were not evaluated as they are not compulsory but should be only ‘considered’. We did 
not evaluate item 6b as none of the studies included were matched.  
 
The reporting quality of the papers was insufficient (Table 1). Only three (0.8%) of the 369 
included papers mentioned the STROBE statement in the text, and none of them stated using 
any other reporting guideline. Of the 100 subsampled publications, only 15% included all the 22 
items mentioned in the STROBE checklist. The median number of elements missing from the 
checklist was 4 (IQR 1-6). The most frequently missed items were a correct description of the 
efforts to address potential sources of bias (item 9, missing in 42%), the study size explanation 
(item 10, missing in 36%), description of the statistical methods (item 12, missing in 62%), of the 
study participants’ characteristics (item 14, missing in 44%), and the discussion of the 
generalisability of the study findings (item 21, missing in 49%). For the reporting of statistical 
methods and the descriptive data of the study participants (items 12 and 14), one frequent flaw 
was the lack of description of the number of participants with missing data for each variable 
(item 14b, missing in 41%) and the explanation of how the missing data were addressed (item 




    
 
 
Table 2: Association between studies’ and journal’s characteristics, and the total score on 
STROBE reporting recommendations for cohort studies’ checklist from a Poisson regression 
(N=100) 
 STROBE score Poisson regression 
 Median IQR Crude IRR 
(95% CI) 
Global  
P value##  
Society journal: Yes 18 16-21 1.0 (0.9-1.1) 0.562 
                             No 18 15-20   
Journal reporting recommendation     
        None 17 16-18 (ref) 0.698 
        Follow any 19 16-21 1.1 (0.9-1.2)  
        Follow STROBE 18 15-21 1.0 (0.9-1.2)  
        Attach STROBE checklist 19 14-20 1.0 (0.8-1.2)  
Impact factor   1.0 (1.0-1.1) 0.387 
Percentage ranking   1.0 (1.0-1.0) 0.279 
Journal category
#
     
    Respiratory 18 15-20 (ref) 0.762 
    Allergy 18 16-20 1.0 (0.9-1.2)  
    Paediatrics 18 16-20 1.0 (0.9-1.2)  
    General medicine 18 14-20 1.0 (0.8-1.2)  
    Infectious diseases 15 15-15 0.9 (0.5-1.4)  
    Pub health/epidemiology/environment 19 18-21 1.1 (0.9-1.2)  
    Other 22 15-22 1.1 (0.9-1.3)  
Continent of study     
    Europe 20 17-21 (ref) 0.493 
    North America 19 16-21 1.0 (0.9-1.1)  
    South America 15 14-16 0.8 (0.6-1.1)  
    Africa 16 16-18 0.9 (0.7-1.1)  
    Asia 18 13-18 0.9 (0.7-1.03)  
    Pacific 16 15-18 0.9 (0.8-1.1)  
    Several 21 15-21 1.0 (0.8-1.3)  
Research question     
    Aetiology 19 17-21 (ref) 0.078 
    Natural history / prognosis  18 16-20 1.0 (0.9-1.1)  
    Diagnosis 14 14-14 0.7 (0.4-1.3)  
    Treatment effects 16 15-17 0.8 (0.7-0.97)  
Main diagnosis of interest     
    Asthma or wheeze 19 16-21 (ref) 0.825 
    Respiratory infectious diseases 18 16-18 0.9 (0.8-1.1)  
    Rare diseases* 18 15-21 1.0 (0.9-1.1)  
    Lung function (healthy children) 20 20-21 1.1 (0.9-1.4)  
    Other** 17 16-21 1.0 (0.8-1.2)  
*Rare diseases include: bronchopulmonary dysplasia, diaphragmatic hernia, cystic fibrosis and primary 
ciliary dyskinesia. **Other diagnoses include: cough, respiratory distress syndrome, pneumothorax and 
unspecific respiratory symptoms. #Categories according to the InCites Journal Citation Report, if a 
journal appeared in 2 categories, it was classified as the first in which it appears in this order: 
respiratory, allergy, infectious diseases, public health/epidemiology/environment, paediatrics, general 
medicine and any other category.  ##: Estimated with the likelihood ratio test. IQR: inter-quartile range, 





Table 2 shows the results of the univariable Poisson regression analysis of the factors associated 
with the number of reported items from the STROBE checklist for cohort studies. None of the 
studied factors was clearly associated with the STROBE score. The journal’s characteristics 
(belonging to a society, impact factor, percentage ranking and journal category), continent of  
study and main diagnosis of interest were not associated with the STROBE score. Only studies 
on treatment effects had a lower score (poorer reporting) when compared to those with an 
aetiological research question (IRR 0.8, 95% CI 0.7-0.97). Table 3 shows the association between 
these same characteristics and the reporting of 4 specific items (those that had been reported 
in less than 60% of the manuscripts). As previously, most tested factors were not associated 
with the reporting of any of the 4 specific items, except for the location of the study, showing a 
smaller odds to report these items if the study was undertaken in Africa, Asia or the Pacific, 
compared to Europe. The study of treatment effects or of natural history of disease/prognosis 
vs. aetiology, had also a lower odds of reporting 3 of the items. As for the journal reporting 
recommendations, manuscripts published in journals that recommended following any 
reporting guideline were more likely to discuss the generalisability of the study findings 













Table 3: Association between studies’ and journal’s characteristics, and reporting of the 4 most 
poorly reported items (<60% of the manuscripts) from a logistic regression (N=100). 
 Crude OR (95%CI) for reporting items 








Society journal 1.7 (0.7-3.8) 1.7 (0.7-3.9) 1.0 (0.5-2.3) 1.1 (0.5-2.4) 
Journal reporting 
recommendation 
    
        None (ref) (ref) (ref) (ref) 
        Follow any guideline 3.0 (0.9-9.5) 1.1 (0.4-3.6) 1.2 (0.4-3.8) 3.7 (1.1-12.1) 
        Follow STROBE 2.0 (0.6-6.1) 1.1 (0.3-3.4) 0.7 (0.2-2.3) 1.2 (0.4-3.8) 
        Attach STROBE checklist 1.4 (0.3-5.9) 0.9 (0.2-3.9) 0.7 (0.2-3.1) 1.7 (0.4-7.4) 
Impact factor 1.1 (0.96-1.2) 1.1 (0.99-1.2) 1.0 (0.9-1.1) 1.1 (0.99-1.2) 
Percentage ranking 1.0 (0.9-1.03) 1.0 (1.0-1.0) 1.0 (1.0-1.0) 1.0 (1.0-1.0) 
Journal category*     
    Respiratory (ref) (ref) (ref) (ref) 
    Allergy 2.3 (0.8-6.7) 1.6 (0.5-5.0) 1.8 (0.6-5.1) 0.6 (0.2-1.8) 
    Paediatrics 0.9 (0.3-3.4) 1.3 (0.3-5.1) 1.5 (0.4-5.3) 0.4 (0.1-1.6) 
    General medicine 0.5 (0.08-3.5) 2.6 (0.4-15.9) 1.3 (0.2-7.6) 0.3 (0.05-2.2) 
    Infectious diseases - - - - 
    Pub health/epidemiology/ 
           environment 
4.9 (0.9-27.3) 1.5 (0.3-6.6) 2.2 (0.5-9.6) 0.8 (0.2-3.3) 
    Other 1.3 (0.3-5.4) 4.5 (1.0-20.3) 3.4 (0.7-15.9) 1.2 (0.3-5.1) 
Continent of study     
    Europe (ref) (ref) (ref) (ref) 
    North America 0.4 (0.1-1.03) 0.5 (0.2-1.3) 0.7 (0.3-1.9) 1.4 (0.6-3.7) 
    South America 0.4 (0.2-6.8) - - - 
    Africa 0.1 (0.01-0.97) 0.6 (0.9-4.0) 0.8 (0.1-5.7) 0.6 (0.1-4.0) 
    Asia 0.2 (0.05-0.9) 0.1 (0.01-0.8) 0.5 (0.1-1.8) 0.1 (0.01-0.8) 
    Pacific 1.3 (0.2-7.6) 0.5 (0.1-2.1) 0.2 (0.02-0.9) 3.1 (0.6-17.2) 
    Several 0.8 (0.06-9.5) 0.5 (0.04-5.4) 1.1(0.1-13.7) 0.5 (0.04-5.4) 
Research question     
    Aetiology (ref) (ref) (ref) (ref) 
    Natural history / prognosis  1.0 (0.4-2.4) 0.4 (0.2-0.97) 0.7 (0.3-1.6) 1.0 (0.4-2.4) 
    Diagnosis - - - - 
    Treatment effects 0.2 (0.04-0.7) - 0.2 (0.07-0.9) 0.4 (0.1-1.3) 
Main diagnosis of interest     
    Asthma or wheeze (ref) (ref) (ref) (ref) 
    Respiratory infectious dis. 1.0 (0.3-3.4) 0.6 (0.2-2.0) 1.1 (0.3-3.6) 0.2 (0.06-0.98) 
    Rare diseases* 1.2 (0.4-3.7) 0.5 (0.2-1.6) 0.6 (0.2-1.7) 1.2 (0.4-3.5) 
    Lung function (healthy) - 2.5 (0.2-28.7) 1.3 (0.1-15.3) 1.6 (0.1-18.9) 
    Other** 3.0 (0.6-15.9) 0.2 (0.2-1.3) 0.3 (0.07-1.4) 0.7 (0.2-2.7) 
*Rare diseases include: bronchopulmonary dysplasia, diaphragmatic hernia, cystic fibrosis and primary 
ciliary dyskinesia. **Other diagnoses include: cough, respiratory distress syndrome, pneumothorax and 
unspecific respiratory symptoms. #Categories according to the InCites Journal Citation Report, if a 
journal appeared in 2 categories, it was classified as the first in which it appears in this order: 
respiratory, allergy, infectious diseases, public health/epidemiology/environment, paediatrics, general 







Summary of main findings 
This systematic review found that reporting quality of cohort studies on paediatric lower 
respiratory problems was insufficient; only 15% of the manuscripts included all the 
recommended items from the STROBE checklist and 42-63% missed specific items such as a 
correct description of statistical methods. Most published paediatric cohort studies were based 
in Europe and North America, answering research questions on aetiology and risk factors, and 
centred on asthma or wheeze. The most frequently used design were birth cohorts with only 
limited use of alternative strategies that may reduce the costs of cohort studies, such as record 
linkage or nested case-control studies. Finally, most studies were published in specialised 
respiratory or allergy journals. 
 
Interpretation of results 
During the screening process, we found that one fifth (101) of the 521 excluded full-text papers 
were actually not cohort studies (77) or did not use a longitudinal analysis (24), despite 
appearing in a search using specific search terms such as “cohort” or “follow-up”, and although 
we had already excluded papers based on the information in the title or abstract.  This was 
sometimes due to the incorrect use of the word “cohort” and the absence of a clear description 
of the study design in the abstract or title. This information was still missing in 17% of the 
included manuscripts. The cohort studies on paediatric lower respiratory problems in 2018 that 
we analysed, focused mostly on aetiology of asthma and were based in Europe or North 
America. Lower respiratory infectious diseases, such as pneumonia or tuberculosis, which are a 
major cause of death in children under 5 years of age worldwide [9], were the focus of only 15% 
of the studies. This may be because most of the studies are based in high income countries, 
whereas the burden of respiratory infectious diseases is much higher in low and middle-income 
countries [9]. The most commonly used design was the birth or pregnancy cohort study. This is 
 
 
an excellent design to study early life factors and their influence on disease, but also quite 
expensive as it needs a large sample size to achieve an adequate number of children with a 
specific outcome and a long follow-up. Adaptations of cohort studies that are cheaper such as 
case-control studies nested in cohort studies were rarely used (3%). Linking available routine 
data is often an elegant way to obtain a cohort dataset with little or no selection bias or 
attrition bias, and achieve large sample sizes at a low cost (even whole population studies)[10]. 
As a disadvantage, studies based on linked routine data often lack clinically relevant details on 
exposure and outcome, resulting in measurement bias. This design was used in one quarter (85) 
of the included studies, and limited to countries with adequate electronic record keeping and 
unique personal identifiers (such as the social security number) that enables linkage between 
different datasets. 
Even though reporting quality of observational studies improved after the publication of the 
STROBE statement [6], current studies in different medical fields have shown that adherence to 
STROBE reporting criteria remains poor or at most moderate [2-7,11-15]. Poor reporting quality 
does not necessarily imply that the conduct and analysis of the study has been poor. On the 
other hand, a high STROBE score does not allow to conclude that the study planning and 
conduct have been excellent. But good reporting is essential, as it enables readers and 
reviewers to assess the quality and risk of bias of a study. For example, we cannot assess 
attrition bias if authors do not report how many participants were lost to follow-up in a cohort 
study. There are multiple tools available to assess the methodological quality or the risk of bias 
of observational studies [16], such as the Newcastle-Ottawa Scale, an easy tool that assesses 
the quality of non-randomised studies included in a systematic review based on the selection 
of the study groups, the comparability of the groups, and the ascertainment of the exposure or 
outcome of interest [17]. The items we identified as being frequently missed, such as the 
description of statistical methods, the sample size estimation or the potential sources of bias 
have been also reported in previous studies [3,6,7,11,12,14,15]. These items are essential to 
 
 
enable other researchers to reproduce the study and to evaluate its internal and external 
validity. The handling of missing information was insufficiently reported in the papers included 
in this review, both in the methods (43% of papers) and results (59%) section, resulting in a 
possible source of bias. Missing data and loss to follow up are common limitations of cohort 
studies, but the implementation of specific statistical strategies, like multiple imputation or 
inverse probability weighting [18], may attenuate its impact. Reporting bias and confounding is 
even more important in cohort studies analysing causal associations. Experts recommend 
specific strategies for adequate variable selection and interpretation of results in causal 
inference studies, such as the use of Direct Acyclic Graphs to identify possible confounders and 
mediators [19], and the presentation of effect estimates with their measures of variability 
(confidence intervals) instead of P values in isolation [20]. These strategies were discussed in a 
recent editorial by editors of respiratory, sleep, and critical care journals, where they also 
highlighted the importance of adhering to STROBE guidelines when reporting sources of bias 
and confounding [21]. 
A plausible reason for not reporting all the STROBE items may be the limitation of manuscript’s 
length, reducing the amount of information that may be included in the paper. Although most 
journals offer the possibility of including supplementary online text and tables, they should 
adjust their policies and guidelines to ensure authors are able to comply with reporting 
guidelines. For example, to allow longer titles to include the study design, and longer methods 
sections to encourage a more detailed description of the statistical methods (e.g. handling of 
missing data and identification of confounders). On the other hand, authors may not be aware 
of the existence of the STROBE statement [22] or they may deliberately omit certain 
information such as missing data to increase the publication chances. In this case, it is the 
journals’ responsibility to inform the authors about the different reporting guidelines for each 
study design. Cohort studies may need to also adhere to other reporting guidelines depending 
on the aim of the manuscript, such as the TRIPOD (Transparent reporting of a multivariable 
 
 
prediction model for individual prognosis or diagnosis)[23], or to specific STROBE extensions, 
such as RECORD (REporting of studies Conducted using Observational Routinely-collected 
health Data)[24]. There are several other STROBE extensions for specific clinical areas, but these 
all include additional criteria to the basic STROBE checklist, so the standard criteria remain valid. 
We did not assess the adherence to any other reporting guideline, but none of the 100 
subsampled manuscripts stated using them. These reporting guidelines are all listed in the 
EQUATOR (Enhancing the QUAlity and Transparency Of health Research) Network homepage 
[25]. Journals should promote adherence to reporting guidelines through a compulsory 
attachment of the reporting checklist at submission and as an online supplement for readers. In 
addition, journals should implement further measures such as involving reviewers in checking 
reporting quality or even employing a journal methodologist to check manuscripts substantially 
before final acceptance. Only by applying this measure in a strict way, as it is done with 
randomized controlled trials, will the reporting quality of observational studies improve and 
become standardised. 
Quality of reporting was not associated with the characteristics of the journal in our study. It did 
not depend on the journal’s impact factor, percentage ranking, society ownership, category (by 
subject), or reporting recommendations. Similarly, it was not associated with the study’s 
location, research question or main diagnosis of interest, except for a decreased STROBE score 
of papers reporting on treatment effects compared to aetiology. Previous studies have found 
quality of reporting of observational studies to be associated with some of these factors, such 
as the journal’s impact factor [7] and authors guidelines [6], the publication type (peer-
reviewed vs report) [3,5] or the author’s affiliation (public health agency vs academic) [5]. 
However, these findings are not consistent [15] and are sometimes based on small samples 
(<80 manuscripts) in specific fields. This shows that reporting quality of cohort studies in 




Strengths and limitations 
This systematic review is the first to describe the characteristics of cohort studies reporting on 
paediatric lower respiratory problems published recently and to assess their reporting quality 
according to the STROBE statement. We collected detailed information on a large number of 
studies published worldwide. However, the review has some limitations. First, we did not 
extend our search to specific databases from South America, Africa or Asia and limited the 
included studies to those published in English. This may have been one of the reasons for the 
under-representation of these regions of the world. However, the most important and relevant 
studies are normally published in English and indexed in Medline or Embase to increase 
accessibility. Second, the large number of studies included precluded a duplicate screening and 
data extraction. This may be more relevant for the evaluation of the STROBE checklist items, 
some of which may be rather subjective. However, all assessors were from the same research 
team; we used well-defined criteria for manuscript inclusion and exclusion, and for the 
assessment of adherence to each of the STROBE checklist’s elements; and papers where the 
assessor was uncertain, were discussed in the team until agreement was reached.. Third, the 
criteria we used to evaluate the adherence to each of the STROBE checklist’s items were not 
very strict. For example, when evaluating the information on confounders or reporting of 
limitations, we only evaluated if confounders were considered or if limitations were mentioned. 
We did not study in detail each manuscript to assess if the confounders included or the 
limitations described were correct and complete. Therefore, our evaluation of the reporting 
quality is quite optimistic and reporting quality may be even poorer. 
 
Conclusion 
The findings of this review may inform both authors and editors on how to increase reporting 
quality of papers of cohort studies reporting on paediatric lower respiratory problems and what 
areas of research are neglected. Researchers should follow reporting guidelines (either STROBE 
 
 
or as appropriate) closely when submitting a manuscript and should check these when 
reviewing other researchers’ manuscripts. The use of nested case-control studies, well designed 
retrospective chart reviews and linkage of routine data with study data should be borne in mind 
when designing a cohort study to reduce costs. On the other side, editors from international 
journals should encourage the publication of studies focused on lower respiratory infections 
and rare diseases, and those based in low and middle-income countries. Journals should not 
only endorse the STROBE statement for the reporting of cohort studies, but should demand 
authors to attach the STROBE checklist during the submission process and ask reviewers to 
report any missing item in the manuscript. Only through a joined effort of editors, reviewers 
and authors may we improve the reporting quality of paediatric cohort studies on respiratory 
problems. 
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Records after duplicates removed 
(n = 15 846) 
Records screened 
(n = 15 846) 
Records excluded 
(n = 14 956) 
Full-text articles assessed 
for eligibility 
(n = 890) 
Full-text articles excluded (n = 521) 
         5 Full-text not available 
         4 Language not English 
       12 Non-original papers 
     116 Subjects >18 years old 
       77 Not a cohort study 
       25 Neither exposures or outcomes  
             related to lower respiratory disease 
     184 <3 months follow-up time 
       14 Underlying non-respiratory chronic  
             disease 
       60 Small sample size (<50 participants) 
       24 No longitudinal analysis 
 
Studies included in 
qualitative synthesis  
(n = 369) 
Analysis of reporting quality 
according to STROBE 
recommendations, random 
subsample (n = 100) 
Fig. 2: Characteristics of cohort studies reporting on paediatric respiratory problems in 2018 (N= 369) 
 
*Rare diseases include: bronchopulmonary dysplasia, diaphragmatic hernia, cystic fibrosis and primary ciliary dyskinesia. 
**Other diagnoses include: cough, respiratory distress syndrome, pneumothorax and unspecific respiratory symptoms. 
#Categories according to the InCites Journal Citation Report, if a journal appeared in 2 categories, it was classified as the 
first in which it appears in this order: respiratory, allergy, infectious diseases, public health/epidemiology/environment, 
paediatrics, general medicine and any other category. IQR: inter-quartile range, RCT: randomized controlled trial. 
N
Location
    Europe 161
    North America 108
    Asia 37
    Pacific 27
    Africa 17
    South America 12
    Several continents 7
Sample size (median, IQR) (N= 368) 746 (188-4535)
Sample size category (N= 368)
    <100 48
    100 - 999 160
    1 000 - 9 999 88
    ≥ 10 000 72
Study design
    Birth/pregnancy cohort 152
    Clinical cohort (prospective) 109
    Population-based cohort (after birth) 56
    Retrospective chart review 35
    RCT with continued follow-up 10
    Nested case-control study 7
Linkage with routine data (N = 367) 85
Research question
    Aetiology/ risk factors / genetics 194
    Natural history / prognosis / trajectories 116
    Treatment effects 52
    Diagnosis 4
    Disease phenotyping 3
Main diagnosis of interest
    Asthma or wheeze 214
    Rare diseases* 64
    Respiratory infectious diseases 55
    Lung function (healthy children) 14
    Other diagnoses** 22
Source of baseline data (multiple possible)
    Questionnaire / interview 128
    Direct examination /laboratory /diagnostic tests 134
    Hospital record 91
    Linkage of routine datasets 66
    Treatment given 23
Source of outcome data (multiple possible)
    Questionnaire / interview 157
    Direct examination /laboratory /diagnostic tests 83
    Hospital record 66
    Linkage of routine datasets 63
Follow-up time, years (median, IQR) (N= 361) 5 (1-10)
Journal category# (multiple possible)
     Respiratory 103
     Allergy / Immunology 88
     Paediatrics 57
     Pub health / epidemiology / environment 37
     Infectious diseases 14
     General Medicine 23









































































Figure 3: Type of research question (A) and sample size (B) by diagnosis of interest, of cohort 
studies reporting on paediatric respiratory outcomes or exposures in 2018 (N= 369). 
The number inside each bar is the total number of manuscripts for each section. 
  
Supplementary Text 
Search terms used for Medline (Ovid) 
1. exp cohort studies / 
2. (cohort* or  prospectiv* or  longitudinal* or  nested or retrospectiv* or  follow*).ti,ab,kw. 
3. exp pediatrics/  or  exp adolescent/ or exp child/ or exp infant/ 
4. (toddler* or infan* or child* or schoolchild* or adolescen* or teen* or pediatr* or 
paediatr*).ti,ab,kw 
5. exp "Respiratory Tract Diseases"/ or exp "signs and symptoms, respiratory"/ 
6. (asthma* or wheez* or bronch* or trache* or laryng* or "vocal cord*" or "primary ciliary 
dyskinesia" or "cystic fibrosis" or "lung disease*" or "lung infection" or respirat* or cough* or dyspn* 
or pneumo* or pleura* or pulmonar* or chest or thora* or empyema or "lung abscess" or legionell* 
or tuberculos* or aspergill* or blastomycos* or "syncytial virus").ti,ab,kw. 
7. exp Respiratory Function Tests/ 
8. ("Airway Resistance" or "Blood Gas Analysis" or Oximetry or Capnography or "Exercise Test*" or 
"Lung Compliance" or "Lung Volume" or "Lung Capacity" or Plethysmography or "Ventilation-
Perfusion" or "forced expiration" or "expiratory flow" or "expiratory volume" or "Maximal Voluntary 
Ventilation" or "maximal expiratory" or spirometry or "Valsalva Maneuver" or "lung function" or 
"lung examination" or sputum or "lung biopsy" or "multiple breath washout" or "transthoracic" or 
"lung angiography" or "lung lavage").ti,ab,kw. 
9. exp respiration/ 
10. (breathing or "breath holding" or exhalation or inhalation or "mucociliary clearance" or "lung 
clearance" or "lung diffusion" or "lung gas exchange" or "lung mechanics" or "lung 
ventilation").ti,ab,kw. 
11. 1 or 2 
12. 3 or 4 
13. 5 or 6 or 7 or 8 or 9 or 10 
14. 11 and 12 and 13 
15. limit 14 to english language 
16. limit 15 to year=’2018’ 
 








Supplementary Table 1: Classification of journals according to the categories used by the In Cites 
Journal Citation Report. 
 Respiratory - American Journal of Respiratory & Critical Care Medicine 
- Annals of the American Thoracic Society 
- BMC Pulmonary Medicine 
- ERJ Open Research 
- European Respiratory Journal 
- International Journal of Tuberculosis & Lung Disease 
- Journal of Asthma 
- Journal of asthma and allergy 
- Journal of Cystic Fibrosis 
- Journal of Thoracic Disease 
- NPJ Primary Care Respiratory Medicine 
- Pediatric Pulmonology 
- Respiratory Care 
- Respiratory Medicine 
- Respiratory Physiology & Neurobiology 
- Respiratory Research 
- The Lancet Respiratory Medicine 
- Thorax 
Allergy/immunology - Allergologia et Immunopathologia 
- Allergology International 
- Allergy 
- Allergy & Asthma Proceedings 
- Allergy: European Journal of Allergy and Clinical Immunology 
- Annals of Allergy, Asthma, & Immunology 
- Asian Pacific Journal of Allergy & Immunology 
- Asim, Allerji, Immunoloji 
- Clinical & Experimental Allergy 
- Journal of Allergy & Clinical Immunology 
- Journal of Allergy & Clinical Immunology: In practice 
- Journal of Immunology 
- Journal of Investigational Allergology & Clinical Immunology 
- Pediatric Allergy & Immunology 
- World Allergy Organization Journal 
Epidemiology, 
public health and 
environmental 
- American Journal of Epidemiology 
- BMC Public Health 
- Clinical Epidemiology 
- Epidemiology 
- Epidemiology & Infection 
- European Journal of Epidemiology 
- International Journal of Epidemiology 
- Iranian Journal of Allergy Asthma & Immunology 
- Journal of Epidemiology & Community Health 
- Public Health 
- Archives of Environmental & Occupational Health 
- Atmospheric Environment 
- Environment International 
- Environmental Epidemiology 
- Environmental Health Perspectives 
- Environmental Health: A Global Access Science Source 
- Environmental Research 
- Environmental Science & Pollution Research 
- International Journal of Environmental Research & Public Health 
- Science of the Total Environment 
Paediatrics - Acta Paediatrica 
- American Journal of Perinatology 
- Archives of Disease in Childhood 
- BMC Pediatrics 
- BMJ Paediatrics Open 
- Clinical Pediatrics 
- Early Human Development 
- Egyptian Pediatric Association Gazette 
- European Journal of Pediatrics 
- International Journal of Pediatrics 
- Jornal de Pediatria 
- Journal of Adolescent Health 
- Journal of Pediatrics 
- Journal of Perinatology 
- Maternal & Child Health Journal 
- Minerva Pediatrica 
- Neonatology 
- Paediatrics & Child Health 
- Pediatric Research 
- Pediatrics 
- Pediatrics & Neonatology 
- Prenatal Diagnosis 
- Revista Paulista de Pediatria 
- The Lancet Child & Adolescent Health 
Infectious diseases - AIDS Research & Human Retroviruses 
- Antibiotics 
- Clinical Infectious Diseases 
- Emerging Infectious Diseases 
- European Journal of Clinical Microbiology & Infectious Diseases 
- Journal of Infectious Diseases 
- Journal of Medical Virology 
- Journal of Microbiology, Immunology & Infection 
- Open Forum Infectious Diseases 
- Pediatric Infectious Disease Journal 
- Vaccine 
General Medicine - African Health Sciences 
- BioMed Research International 
- Bjgp Open 
- BMJ Open 
- Bosnian Journal of Basic Medical Sciences 
- Colombia Medica 
- Cureus 
- Eastern Mediterranean Health Journal 
- eLife 
- Eurosurveillance 
- International journal of general medicine 
- JAMA Pediatrics 
- Jci Insight 
- Nature Communications 
- PeerJ 
- PLoS ONE 
- Revista Da Associacao Medica Brasileira 
- Sao Paulo Medical Journal = Revista Paulista de Medicina 
- Saudi Medical Journal 
- Scientific Reports 
- Southern Medical Journal 
Other - Acta Obstetricia et Gynecologica Scandinavica 
- American Journal of Clinical Nutrition 
- American Journal of Managed Care 
- American Journal of Obstetrics & Gynecology 
- American Journal of Respiratory Cell & Molecular Biology 
- American Journal of Tropical Medicine & Hygiene 
- Annals of Behavioral Medicine 
- Annals of Surgery 
- Arthritis care & research 
- British Journal of Dermatology 
- British Journal of Nutrition 
- CJEM Canadian Journal of Emergency Medical Care 
- Clinical Nutrition 
- Clinical Otolaryngology 
- ClinicoEconomics and Outcomes Research 
- CMAJ 
- European Journal of Clinical Nutrition 
- European Journal of Obstetrics, Gynecology, & Reproductive Biology 
- European Journal of Psychotraumatology 
- European Radiology 
- Frontiers in Pharmacology 
- Frontiers in Physiology 
- Health Promotion Practice 
- Health Services Insights 
- Hypertension 
- International Journal of Eating Disorders 
- Journal of Laparoendoscopic & Advanced Surgical Techniques. 
- Journal of Pediatric Gastroenterology & Nutrition 
- Journal of Pediatric Nursing 
- Journal of Pediatric Surgery 
- Journal of Racial & Ethnic Health Disparities 
- Journal of Voice 
- Maternal & Child Nutrition 
- Metabolomics 
- Nature Plants 
- Nutrients 
- Oncotarget 
- Orphanet Journal Of Rare Diseases 
- Pediatric Critical Care Medicine 
- Pharmacoepidemiology & Drug Safety 
- Postepy Dermatologii I Alergologii 
- Psychology & Health 
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Location        
    Europe 45 (44) 
(44) 
40 (45) 3 (21) 17 (46) 23 (40) 6 (26)  27 (57) 
    North America 31 30 21 (24) 6 (43) 9 (24) 23 (40) 6 (26)   12 (26) 
    South America 2 (2) 3 (3)             0              0  3 (5) 4 (17)             0 
    Africa 4 (4) 5 (6)             0  3 (8) 1 (2) 3 (13)       1 (2) 
    Asia 6 (6) 14 (16) 2 (14) 4 (11) 3 (5) 4 (17)       4 (9) 
    Pacific 10 (10)  4 (5) 3 (21) 3 (8) 4 (7) 0       3 (6) 
    Several continents 5 (5) 1 (1) 0 1 (3)              0 0            0 























Sample size category (N= 368)        
    <100 20 (19) 5(6) 1 (7) 1 (3) 8 (14) 6 (26)      7(15) 
    100 - 999 42 (41) 46 (52) 5 (36) 11 (30) 26 (46) 8 (35) 22(47) 
    1 000 – 9 999 28 (27) 25 (28) 4 (29) 11 (30) 10 (18) 3 (13) 7(15) 
    ≥ 10 000 13 (13) 12 (14) 4 (29) 14 (38) 13 (23) 6 (26) 11(23) 
Study design        
    Birth/pregnancy cohort 44 (43) 42 (48) 2 (14) 20 (54) 22 (39) 5 (22) 17(36) 
    Population-based (after birth) 12 (12) 10 (11) 2 (14) 10 (27) 8 (14) 6 (26) 8(17) 
    Clinical cohort (prospective) 31 (30) 28 (32) 9 (64) 6 (16) 14 (25) 7 (30) 14(30) 
    Retrospective chart review 13 (13)             0             0              0 12 (21) 4 (17) 6(13) 
    Nested case-control 1 (1) 3(3) 1(7)             0              0  1 (4) 1(2)  
    RCT with continued follow-up 2 (2) 5 (6) 0  1(3) 1 (2)             0  1(2) 





19 (22) 5 (36) 10 (27) 13 (23) 5 (22) 15(32) 
 
 
      
Research question        
    Aetiology 42(41) 
(40) 
50 (57) 4 (29) 27 (73) 27 (47) 15 (65) 29(62) 
    Natural history / prognosis  40 39
(40) 
28 (32) 7 (50) 4 (11) 20 (35) 4 (17) 13(28) 
    Diagnosis 4 (4 0 0 0 0 0 0 
    Treatment effects 17(17) 
(17) 
8 (9) 3 (21) 5 (14) 10 (18) 4 (17) 5 (11) 
    Aetiology 0 2 (2) 0       1 (3) 0 0  0 
Main diagnosis of interest        
    Asthma or wheeze 56 (54) 
(56) 
72 (82) 1(7) 25 (68) 22 (39) 13 (57) 25(53) 
    Respiratory infectious dis. 7 (7 11 (13) 9 (64) 5 (14) 14 (25) 4 (17) 5 (11) 
    Rare diseases* 27(26) 
(24) 
            0 4 (29)             0 16 (28) 4 (17) 13(28) 
    Lung function (healthy) 7 (7 1 (1) 0 4 (11) 0             0  2 (4) 
    Other** 6 (6) 4 (5) 0  3 (8) 5 (9) 2 (9)        2 (4) 
# Figures represent ‘n (%)’ unless otherwise stated *Rare diseases include: bronchopulmonary dysplasia, 
diaphragmatic hernia, cystic fibrosis and primary ciliary dyskinesia. **Other diagnoses include: cough, 
respiratory distress syndrome, pneumothorax and unspecific respiratory symptoms. IQR: inter-quartile range, 
RCT: randomized controlled trial, CF: cystic fibrosis, PCD: Primary ciliary dyskinesia. 
 
 
 
 
 
 
 
